Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance provided a corporate update and reported its third quarter 2024 financial results. Key highlights include:
Merger Agreement: Revance and Crown Laboratories entered into a merger agreement, with Crown offering $6.66 per share for all outstanding Revance shares. The tender offer deadline was extended to November 12, 2024.
Distribution Agreements: Revance amended its agreement with Teoxane for U.S. distribution of RHA® dermal fillers and signed a new exclusive agreement for DAXXIFY® distribution in Australia and New Zealand.
China Approval: DAXXIFY was approved in China for improving glabellar lines.
Financials: Q3 2024 net revenue was $59.9 million, up 11% from Q3 2023. However, the company reported a net loss of $38.1 million. SG&A expenses decreased to $62.6 million, and R&D expenses were $11.4 million.
Guidance Withdrawn: Revance withdrew its 2024 financial guidance and will not hold a conference call for Q3 results.
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced a merger agreement, with Crown offering to acquire all outstanding Revance shares for $6.66 per share in cash. This represents a total enterprise value of $924 million and a 89% premium over Revance's closing price on August 9, 2024. The merger aims to create a leading, innovative aesthetics and skincare company, combining Crown's skincare products with Revance's aesthetics offerings.
The combined company will feature flagship brands including DAXXIFY®, RHA® Collection, SkinPen®, PanOxyl®, Blue Lizard®, and StriVectin®. It will have global commercialization capabilities, covering over 10,000 medical professionals and various retail channels. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances.
Revance Therapeutics (NASDAQ: RVNC) reported Q2 2024 financial results with total product revenue of $65.3 million, up 20% YoY. DAXXIFY net revenue reached $28.7 million, a 27% YoY increase, with aesthetic units sold up 65% YoY. The RHA Collection generated $36.6 million, up 15% YoY. Revance launched DAXXIFY for cervical dystonia, entering the $2.7 billion U.S. therapeutic neurotoxin market. The company maintains its 2024 total net product revenue guidance of at least $280 million. Q2 net loss from continuing operations was $37.5 million, an improvement from $58.2 million in Q2 2023. Cash, cash equivalents, and short-term investments stood at $232.2 million as of June 30, 2024. Revance projects reaching cash flow break-even and positive Adjusted EBITDA in 2025.
Revance Therapeutics (NASDAQ: RVNC) will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close. A conference call and live webcast will follow at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and provide a corporate update.
U.S. callers can dial (833) 470-1428, while international callers can dial (929) 526-1599, using conference ID 218406. The webcast will be accessible through the investor relations section of Revance's website and will be available for replay from August 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET to November 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET. Registration for the replay is required via the webcast link on the events page. The webcast will remain available for 90 days post-event.
Revance Therapeutics (Nasdaq: RVNC) has announced the issuance of 104,800 inducement restricted stock units (RSUs) to 31 new employees. These RSUs will vest over a period of four years, with 25% vesting annually. The grants were approved by Revance's Compensation Committee as an inducement material to the new hires' employment, in compliance with NASDAQ Listing Rule 5635(c)(4).
Revance Therapeutics (NASDAQ: RVNC) announced its participation in two upcoming investor conferences. CFO Tobin Schilke will present at the William Blair 44th Annual Growth Stock Conference on June 4, 2024, in Chicago. CEO Mark J. Foley will speak at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. Live audio webcasts will be accessible via Revance's Investor Relations webpage, with replays available for 90 days post-event.
Revance Therapeutics, Inc. (NASDAQ: RVNC) reported total net product revenue of $51.7 million, with a YoY increase of 13%. DAXXIFY® net revenue was $22.1 million, and RHA® Collection net revenue was $29.6 million. Aesthetic units sold increased by 105% YoY despite seasonality. Revance expects total net product revenue for 2024 to be at least $280 million. Cash, cash equivalents, and short-term investments were $277.1 million as of March 31, 2024.
Revance Therapeutics, Inc. (NASDAQ: RVNC) has launched DAXXIFY for the treatment of cervical dystonia, a long-lasting neurotoxin. The product has secured coverage for 78% of commercial lives, marking the company's entry into the $2.7 billion U.S. therapeutic neurotoxin market. With FDA approval in August 2023, Revance aims to address the unmet needs of patients, physicians, and payers by providing a differentiated treatment option.
Revance Therapeutics, Inc. (NASDAQ: RVNC) will release its first quarter 2024 financial results on May 9, 2024, followed by a conference call and webcast to discuss the results and provide a corporate update. The conference call will be accessible for U.S. callers and other locations, with a webcast replay available for 90 days.
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
